TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors
Publications
TANGENT study design
Emactuzumab for dTGCT Long-Term Study Results
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour
Emactuzumab Phase1 dTGCT
CSF1R inhibition with emactuzumab in locally advanced diff use-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.